Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis

NCT01883999 · View on ClinicalTrials.gov ↗

Study Summary

The Iliac Branch Endoprosthesis (IBE) 12-04 study will be a prospective, nonrandomized, multicenter, single-arm evaluation designed to assess the safety and efficacy of the IBE Device in subjects with common iliac artery aneurysms (CIAA) or aorto-iliac aneurysms (AIA).

Interventions

  • DEVICE GORE® EXCLUDER® Iliac Branch Endoprosthesis

Study Locations (1)

New York

  • Weill Cornell Medical Center — New York

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2013-10
Est. Completion 2021-06
Phase NA

Sponsor

W.L.Gore & Associates

117 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01883999

The ClinicalTrials.gov registry entry for NCT01883999 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W.L.Gore & Associates, which has 117 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Aorto-iliac Aneurysms appearing as the primary indexed condition, and to 1 intervention — of which GORE® EXCLUDER® Iliac Branch Endoprosthesis is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01883999 reports 1 study location spanning 1 distinct geographic area — top geographies include New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01883999 about?

NCT01883999 is a clinical study titled "Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis". The Iliac Branch Endoprosthesis (IBE) 12-04 study will be a prospective, nonrandomized, multicenter, single-arm evaluation designed to assess the safety and efficacy of the IBE Device in subjects with common iliac artery aneurysms (CIAA) or aorto-iliac aneurysms (AIA).

What is the current status of trial NCT01883999?

This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2013-10. Estimated completion is 2021-06.

What conditions does trial NCT01883999 study?

This clinical trial studies the following conditions: Aorto-iliac Aneurysms, Common Iliac Artery Aneurysms. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01883999?

The interventions under investigation include: GORE® EXCLUDER® Iliac Branch Endoprosthesis (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01883999?

This trial is sponsored by W.L.Gore & Associates, which has 117 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01883999 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial